NCT02860039View on ClinicalTrials.gov

High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

December 1, 2021

Study Completion Date

September 30, 2024

Conditions
Hematopoietic Cell Transplantation RecipientMalignant NeoplasmInfluenza
Interventions
BIOLOGICAL

Trivalent Influenza Vaccine

High dose Trivalent Influenza Vaccine given intramuscular

BIOLOGICAL

Quadrivalent Influenza Vaccine

Standard dose Quadrivalent Influenza Vaccine given intramuscular

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (9)

19104

Children's Hospital of Philadelphia, Philadelphia

37232

Vanderbilt-Ingram Cancer Center, Nashville

38105

St. Jude Children's Research Hospital, Memphis

43205

Nationwide Children's Hospital, Columbus

45229

Cincinnati Children's Hospital, Cincinnati

64108

Children's Mercy Hospital, Kansas City

77030

Texas Children's Hospital, Houston

94158

UCSF Children's Hospital, San Francisco

98101

Seattle Children's Hospital Research Institute, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT02860039 - High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant | Biotech Hunter | Biotech Hunter